摘要
目的探讨二甲双胍对T2DM患者血清内脏脂源性丝氨酸蛋白酶抑制剂(vaspin)水平的影响。方法将109例T2DM患者分为二甲双胍治疗(A)组、格列美脲治疗(B)组、饮食运动治疗(C)组,30名健康体检者为对照(D)组。采用ELISA测定各组vaspin水平,分析其与血脂、FPG、2hPG、FIns、BMI、HOMA-IR等的关系。观察A、B、C组治疗前后vaspin水平变化。结果 (1)A组vaspin水平高于D组;vaspin水平女性高于男性;(2)vaspin水平与性别、BMI、WHR、HOMA-IR、FIns呈正相关(P<0.05),与HDL-C呈负相关(P<0.05);(3)A组治疗14周后vaspin水平降低,B组水平无明显变化,C组降低,差异均有统计学意义(P均<0.05);(4)HOMA-IR与BMI是影响vaspin水平的独立相关因素。结论二甲双胍增加T2DM患者IS同时,降低vaspin水平。
Objective To investigate the effect of metformin on the level of plasma vaspin in T2DM patients. Methods Thirty normal subjects were selected as the controls （group D）. The 109 patients with T2DM were randomized into three groups metformin treated group （group A）, glimepiride treated group （group B）, diet and exercise treated group （group C）. The level of plasma vaspin was measured in patients with T2DM and normal subjects by ELISA. The relationship of the level of plasma vaspin with blood lipid, HbAlc, FPG, 2 hPG, BMI, WHR, and HOMA-IR was also analyzed after treatment, and the change in the level of plasma vaspin was observed in the three groups. Results （1） Group A had a higher vaspin level than D group E（0. 78±0. 32） vs （0. 49±0.21）, P〈0. 01]. Vaspin level was higher in female than in male 1-（0. 74±0. 18） vs （0. 47±0. 15）,P〈0. 05）]. （2） The vaspin level was positively correlated with sex, BMI, WHR, HOMA-IR and Fins （r=0. 532, 0. 602, 0. 523, 0. 479, 0. 530, P〈 0. 05）, and negatively correlated with HDL-C （r=-0. 598, P^0. 05）. （3） After the treatment for 14 weeks, the vaspin level in group A was decreased, it was not significantly changed in group B, while it was decreased in group C, and the difference was significant in statistics （P〈0.05）. （4） HOMA-1R and BM1 were independently related factors influencing the level of serum vaspin. Conclusion Metformin can improve insulin resistance as well as reduce the level of plasma vaspin.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2013年第8期705-708,共4页
Chinese Journal of Diabetes
